Elisabeth Buchdunger

23.9k total citations · 6 hit papers
60 papers, 17.4k citations indexed

About

Elisabeth Buchdunger is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Elisabeth Buchdunger has authored 60 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 26 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Elisabeth Buchdunger's work include Chronic Myeloid Leukemia Treatments (33 papers), Chronic Lymphocytic Leukemia Research (20 papers) and HER2/EGFR in Cancer Research (18 papers). Elisabeth Buchdunger is often cited by papers focused on Chronic Myeloid Leukemia Treatments (33 papers), Chronic Lymphocytic Leukemia Research (20 papers) and HER2/EGFR in Cancer Research (18 papers). Elisabeth Buchdunger collaborates with scholars based in Switzerland, United States and Finland. Elisabeth Buchdunger's co-authors include Brian Druker, Nicholas Lydon, J. Zimmermann, Renaud Capdeville, Sayuri Ohno-Jones, Shu Tamura, Hagop M. Kantarjian, J. Ford, Gerald M. Segal and Moshe Talpaz and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Elisabeth Buchdunger

60 papers receiving 16.8k citations

Hit Papers

Efficacy and Safety of a Specific Inhibitor of the BCR-AB... 1996 2026 2006 2016 2001 1996 2002 2000 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
    2001 3.8k citations Brian Druker, Moshe Talpaz et al. New England Journal of Medicine profile →
  2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    1996 2.8k citations Brian Druker, Shu Tamura et al. profile →
  3. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
    2002 1.1k citations Renaud Capdeville, Elisabeth Buchdunger et al. Nature Reviews Drug Discovery profile →
  4. Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
    2000 1.0k citations Elisabeth Buchdunger, Sayuri Ohno-Jones et al. profile →
  5. The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    2004 960 citations Elisabeth Buchdunger, Brian Druker et al. Blood profile →
  6. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    1996 878 citations Elisabeth Buchdunger, J. Zimmermann et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisabeth Buchdunger Switzerland 42 8.7k 5.7k 5.6k 4.4k 3.9k 60 17.4k
Nicholas Lydon Switzerland 29 7.2k 0.8× 3.9k 0.7× 4.8k 0.9× 2.7k 0.6× 3.3k 0.8× 40 12.6k
Renaud Capdeville Switzerland 29 6.8k 0.8× 3.0k 0.5× 5.0k 0.9× 2.8k 0.6× 3.3k 0.8× 52 13.0k
Michael W. Deininger United States 67 16.3k 1.9× 4.9k 0.9× 12.5k 2.2× 3.2k 0.7× 7.5k 1.9× 399 21.2k
Carlo Gambacorti‐Passerini Italy 56 7.9k 0.9× 5.0k 0.9× 5.5k 1.0× 2.9k 0.7× 3.3k 0.8× 342 13.7k
Paul W. Manley Switzerland 50 5.9k 0.7× 3.4k 0.6× 4.2k 0.8× 2.0k 0.4× 2.7k 0.7× 153 10.6k
D. Gary Gilliland United States 76 12.2k 1.4× 12.2k 2.2× 9.6k 1.7× 3.6k 0.8× 4.0k 1.0× 144 22.5k
Debra Resta United States 15 6.2k 0.7× 2.0k 0.3× 4.4k 0.8× 1.8k 0.4× 3.1k 0.8× 24 9.0k
Deborah A. Thomas United States 80 12.3k 1.4× 6.3k 1.1× 10.2k 1.8× 4.9k 1.1× 2.6k 0.7× 451 23.2k
Oliver G. Ottmann Germany 62 10.4k 1.2× 4.9k 0.9× 5.0k 0.9× 4.0k 0.9× 2.8k 0.7× 372 16.1k
Tadeusz Robak Poland 59 5.8k 0.7× 5.3k 0.9× 10.0k 1.8× 5.0k 1.1× 1.2k 0.3× 712 19.3k

Countries citing papers authored by Elisabeth Buchdunger

Since Specialization
Citations

This map shows the geographic impact of Elisabeth Buchdunger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Buchdunger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Buchdunger more than expected).

Fields of papers citing papers by Elisabeth Buchdunger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Buchdunger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Buchdunger. The network helps show where Elisabeth Buchdunger may publish in the future.

Co-authorship network of co-authors of Elisabeth Buchdunger

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Buchdunger. A scholar is included among the top collaborators of Elisabeth Buchdunger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Buchdunger. Elisabeth Buchdunger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gäumann, Andreas, Hannes C. A. Drexler, Sven A. Lang, et al.. (2014). The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®). International Journal of Oncology. 45(6). 2267–2277. 11 indexed citations
2.
Day, Elizabeth, Katrin Spiegel, Paul W. Manley, et al.. (2008). Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. European Journal of Pharmacology. 599(1-3). 44–53. 224 indexed citations
3.
Leipner, Carola, Katja Grün, Andreas J. Müller, et al.. (2008). Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovascular Research. 79(1). 118–126. 29 indexed citations
4.
Houghton, Peter J., Glen S. Germain, Franklin C. Harwood, et al.. (2004). Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro . Cancer Research. 64(7). 2333–2337. 264 indexed citations
5.
O’Reilly, Terry, Markus Wartmann, Saveur-Michel Maira, et al.. (2004). Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemotherapy and Pharmacology. 55(4). 307–317. 24 indexed citations
6.
Buchdunger, Elisabeth, et al.. (2002). Pharmacology of imatinib (STI571). European Journal of Cancer. 38. S28–S36. 214 indexed citations
7.
Manley, Paul W., Sandra W. Cowan‐Jacob, Elisabeth Buchdunger, et al.. (2002). Imatinib: a selective tyrosine kinase inhibitor. European Journal of Cancer. 38. S19–S27. 201 indexed citations
8.
Hiltunen, Mikko, Tuomas T. Rissanen, Juha Rutanen, et al.. (2002). Combination of VEGF-C gene transfer and treatment with the PDGF receptor kinase inhibitor STI571 leads to persistent reduction in neointima formation in balloon-denunded rabbit aorta. Journal of the American College of Cardiology. 39. 69–70. 1 indexed citations
9.
Capdeville, Renaud, Elisabeth Buchdunger, Juerg Zimmermann, & Alex Matter. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery. 1(7). 493–502. 1067 indexed citations breakdown →
10.
Zubay, Geoffrey, Brian Druker, Moshe Talpaz, et al.. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome. 14(13). 733–738. 9 indexed citations
11.
Lemström, Karl, Roope Sihvola, Jussi Tikkanen, et al.. (2001). PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Transplantation Proceedings. 33(1-2). 318–318. 6 indexed citations
12.
Druker, Brian, Moshe Talpaz, Debra Resta, et al.. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine. 344(14). 1031–1037. 3811 indexed citations breakdown →
13.
Buchdunger, Elisabeth, Alex Matter, & Brian Druker. (2001). Bcr-Abl inhibition as a modality of CML therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1551(1). M11–M18. 72 indexed citations
14.
Missbach, Martin, Eva Altmann, Leo Widler, et al.. (2000). Substituted 5,7-diphenyl-pyrrolo[2,3 d ]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorganic & Medicinal Chemistry Letters. 10(9). 945–949. 40 indexed citations
15.
Aavik, Einari, et al.. (1999). Role of Platelet-derived Growth Factor in Obliterative Bronchiolitis (Chronic Rejection) in the Rat. American Journal of Respiratory and Critical Care Medicine. 160(4). 1324–1332. 44 indexed citations
16.
Fabbro, Doriano, Elisabeth Buchdunger, Jürgen Mestan, et al.. (1999). Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent. Pharmacology & Therapeutics. 82(2-3). 293–301. 122 indexed citations
17.
18.
Carroll, Martin, Sayuri Ohno-Jones, Shu Tamura, et al.. (1997). CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins. Blood. 90(12). 4947–4952. 452 indexed citations
19.
Buchdunger, Elisabeth, Helmut Mett, Uwe Trinks, et al.. (1995). 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.. PubMed. 1(8). 813–21. 24 indexed citations
20.
Trinks, Uwe, Elisabeth Buchdunger, Pascal Furet, et al.. (1994). Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. Journal of Medicinal Chemistry. 37(7). 1015–1027. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas Lydon Breakdown of academic impact, for papers by Renaud Capdeville Breakdown of academic impact, for papers by Michael W. Deininger Breakdown of academic impact, for papers by Carlo Gambacorti‐Passerini Breakdown of academic impact, for papers by Paul W. Manley Breakdown of academic impact, for papers by D. Gary Gilliland Breakdown of academic impact, for papers by Debra Resta Breakdown of academic impact, for papers by Deborah A. Thomas Breakdown of academic impact, for papers by Oliver G. Ottmann Breakdown of academic impact, for papers by Tadeusz Robak
Rankless by CCL
2026